Improving the efficacy of cancer immunotherapy

J. Copier, A. G. Dalgleish, C. M. Britten, L. H. Finke, G. Gaudernack, S. Gnjatic, K. Kallen, R. Kiessling, M. Schuessler-Lenz, H. Singh, James E Talmadge, H. Zwierzina, L. Håkansson

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult. The development of cancer vaccines is hampered by a range of issues particular to this field of research. On 12th March 2008, the Biotherapy Development Association convened a workshop to discuss issues faced by scientists and clinicians involved in the development of cancer vaccines. This paper is a review of the field, based on discussions held at the BDA workshop, and describes biological barriers encountered in generating effective immune responses to tumours, methodological obstacles encountered in the improvement of immunological monitoring which aims to improve inter-laboratory and inter-trial comparisons, challenges in clinical trial design and problems posed by the lack of specific regulation for cancer vaccines and the impact on their development. Ultimately, a number of general solutions are posed: (1) better patient selection, (2) use of multi-modal treatments that affect several aspects of the immune system at once, (3) a requirement for the development of good biomarkers to stratify patients for selection prior to trial and as surrogates for clinical response and (4) harmonisation of SOPs for immunological monitoring of clinical trials.

Original languageEnglish (US)
Pages (from-to)1424-1431
Number of pages8
JournalEuropean Journal of Cancer
Volume45
Issue number8
DOIs
StatePublished - May 1 2009

Fingerprint

Cancer Vaccines
Immunotherapy
Immunologic Monitoring
Clinical Trials
Patient Selection
Neoplasms
Education
Biological Therapy
Immune System
Biomarkers
Research
Therapeutics

Keywords

  • Cancer vaccine
  • Clinical response
  • Combination therapy
  • End-points
  • Immunological monitoring
  • Immunosupression
  • Immunotherapy
  • Surrogate end-points

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Copier, J., Dalgleish, A. G., Britten, C. M., Finke, L. H., Gaudernack, G., Gnjatic, S., ... Håkansson, L. (2009). Improving the efficacy of cancer immunotherapy. European Journal of Cancer, 45(8), 1424-1431. https://doi.org/10.1016/j.ejca.2008.12.017

Improving the efficacy of cancer immunotherapy. / Copier, J.; Dalgleish, A. G.; Britten, C. M.; Finke, L. H.; Gaudernack, G.; Gnjatic, S.; Kallen, K.; Kiessling, R.; Schuessler-Lenz, M.; Singh, H.; Talmadge, James E; Zwierzina, H.; Håkansson, L.

In: European Journal of Cancer, Vol. 45, No. 8, 01.05.2009, p. 1424-1431.

Research output: Contribution to journalArticle

Copier, J, Dalgleish, AG, Britten, CM, Finke, LH, Gaudernack, G, Gnjatic, S, Kallen, K, Kiessling, R, Schuessler-Lenz, M, Singh, H, Talmadge, JE, Zwierzina, H & Håkansson, L 2009, 'Improving the efficacy of cancer immunotherapy', European Journal of Cancer, vol. 45, no. 8, pp. 1424-1431. https://doi.org/10.1016/j.ejca.2008.12.017
Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S et al. Improving the efficacy of cancer immunotherapy. European Journal of Cancer. 2009 May 1;45(8):1424-1431. https://doi.org/10.1016/j.ejca.2008.12.017
Copier, J. ; Dalgleish, A. G. ; Britten, C. M. ; Finke, L. H. ; Gaudernack, G. ; Gnjatic, S. ; Kallen, K. ; Kiessling, R. ; Schuessler-Lenz, M. ; Singh, H. ; Talmadge, James E ; Zwierzina, H. ; Håkansson, L. / Improving the efficacy of cancer immunotherapy. In: European Journal of Cancer. 2009 ; Vol. 45, No. 8. pp. 1424-1431.
@article{a6af4e20b98249ac895e0321e59ca257,
title = "Improving the efficacy of cancer immunotherapy",
abstract = "A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult. The development of cancer vaccines is hampered by a range of issues particular to this field of research. On 12th March 2008, the Biotherapy Development Association convened a workshop to discuss issues faced by scientists and clinicians involved in the development of cancer vaccines. This paper is a review of the field, based on discussions held at the BDA workshop, and describes biological barriers encountered in generating effective immune responses to tumours, methodological obstacles encountered in the improvement of immunological monitoring which aims to improve inter-laboratory and inter-trial comparisons, challenges in clinical trial design and problems posed by the lack of specific regulation for cancer vaccines and the impact on their development. Ultimately, a number of general solutions are posed: (1) better patient selection, (2) use of multi-modal treatments that affect several aspects of the immune system at once, (3) a requirement for the development of good biomarkers to stratify patients for selection prior to trial and as surrogates for clinical response and (4) harmonisation of SOPs for immunological monitoring of clinical trials.",
keywords = "Cancer vaccine, Clinical response, Combination therapy, End-points, Immunological monitoring, Immunosupression, Immunotherapy, Surrogate end-points",
author = "J. Copier and Dalgleish, {A. G.} and Britten, {C. M.} and Finke, {L. H.} and G. Gaudernack and S. Gnjatic and K. Kallen and R. Kiessling and M. Schuessler-Lenz and H. Singh and Talmadge, {James E} and H. Zwierzina and L. H{\aa}kansson",
year = "2009",
month = "5",
day = "1",
doi = "10.1016/j.ejca.2008.12.017",
language = "English (US)",
volume = "45",
pages = "1424--1431",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Improving the efficacy of cancer immunotherapy

AU - Copier, J.

AU - Dalgleish, A. G.

AU - Britten, C. M.

AU - Finke, L. H.

AU - Gaudernack, G.

AU - Gnjatic, S.

AU - Kallen, K.

AU - Kiessling, R.

AU - Schuessler-Lenz, M.

AU - Singh, H.

AU - Talmadge, James E

AU - Zwierzina, H.

AU - Håkansson, L.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult. The development of cancer vaccines is hampered by a range of issues particular to this field of research. On 12th March 2008, the Biotherapy Development Association convened a workshop to discuss issues faced by scientists and clinicians involved in the development of cancer vaccines. This paper is a review of the field, based on discussions held at the BDA workshop, and describes biological barriers encountered in generating effective immune responses to tumours, methodological obstacles encountered in the improvement of immunological monitoring which aims to improve inter-laboratory and inter-trial comparisons, challenges in clinical trial design and problems posed by the lack of specific regulation for cancer vaccines and the impact on their development. Ultimately, a number of general solutions are posed: (1) better patient selection, (2) use of multi-modal treatments that affect several aspects of the immune system at once, (3) a requirement for the development of good biomarkers to stratify patients for selection prior to trial and as surrogates for clinical response and (4) harmonisation of SOPs for immunological monitoring of clinical trials.

AB - A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult. The development of cancer vaccines is hampered by a range of issues particular to this field of research. On 12th March 2008, the Biotherapy Development Association convened a workshop to discuss issues faced by scientists and clinicians involved in the development of cancer vaccines. This paper is a review of the field, based on discussions held at the BDA workshop, and describes biological barriers encountered in generating effective immune responses to tumours, methodological obstacles encountered in the improvement of immunological monitoring which aims to improve inter-laboratory and inter-trial comparisons, challenges in clinical trial design and problems posed by the lack of specific regulation for cancer vaccines and the impact on their development. Ultimately, a number of general solutions are posed: (1) better patient selection, (2) use of multi-modal treatments that affect several aspects of the immune system at once, (3) a requirement for the development of good biomarkers to stratify patients for selection prior to trial and as surrogates for clinical response and (4) harmonisation of SOPs for immunological monitoring of clinical trials.

KW - Cancer vaccine

KW - Clinical response

KW - Combination therapy

KW - End-points

KW - Immunological monitoring

KW - Immunosupression

KW - Immunotherapy

KW - Surrogate end-points

UR - http://www.scopus.com/inward/record.url?scp=66549098937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66549098937&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2008.12.017

DO - 10.1016/j.ejca.2008.12.017

M3 - Article

C2 - 19167214

AN - SCOPUS:66549098937

VL - 45

SP - 1424

EP - 1431

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8

ER -